Glioblastoma Multiforme Treatment Market Size, Share & Trends Report

Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Radiation Therapy, Immunotherapy), By Drug Class, By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-4-68039-527-3
  • Number of Pages: 110
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Table of Contents

Chapter 1. Methodology and Scope
                     1.1. Market Segmentation & Scope
                         1.1.1. Treatment
                         1.1.2. Drug class
                         1.1.3. End Use
                         1.1.4. Regional scope
                         1.1.5. Estimates and forecast timeline
                     1.2. Research Methodology
                     1.3. Information Procurement
                         1.3.1. Purchased database
                         1.3.2. GVR’s internal database
                         1.3.3. Secondary sources
                         1.3.4. Primary research
                         1.3.5. Details of primary research
                     1.4. Information or Data Analysis
                     1.5. Market Formulation & Validation
                     1.6. Model Details
                     1.7. List of Secondary Sources
                     1.8. List of Primary Sources
                     1.9. Objectives
Chapter 2. Executive Summary
                     2.1. Market Outlook
                     2.2. Segment Outlook
                         2.2.1. Treatment outlook
                         2.2.2. Drug class outlook
                         2.2.3. End-use outlook
                         2.2.4. Regional outlook
                     2.3. Competitive Insights
Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends & Scope
                     3.1. Market Lineage Outlook
                         3.1.1. Parent market outlook
                         3.1.2. Related/ancillary market outlook
                     3.2. Penetration & Growth Prospect Mapping
                     3.3. Industry Value Chain Analysis
                         3.3.1. Reimbursement framework
                     3.4. Market Dynamics
                         3.4.1. Market Driver Analysis
                         3.4.2. Market Restraint Analysis
                     3.5. Glioblastoma Multiforme Treatment Market Analysis Tools
                         3.5.1. Industry Analysis - Porter’s Five Forces
                             3.5.1.1. Supplier power
                             3.5.1.2. Buyer power
                             3.5.1.3. Substitution threat
                             3.5.1.4. Threat of new entrant
                             3.5.1.5. Competitive rivalry
                         3.5.2. PESTEL Analysis
                             3.5.2.1. Political landscape
                             3.5.2.2. Technological landscape
                             3.5.2.3. Economic Landscape
Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Estimates & Trend Analysis
                     4.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
                     4.2. Glioblastoma Multiforme Treatment Market: Treatment Movement & Market Share Analysis, 2022 & 2030
                     4.3. Surgery
                         4.3.1. Surgery market estimates and forecasts, 2018 to 2030 (USD Million)
                     4.4. Radiation Therapy
                         4.4.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
                     4.5. Chemotherapy
                         4.5.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
                     4.6. Targeted Therapy
                         4.6.1. Targeted Therapy market estimates and forecasts, 2018 to 2030 (USD Million)
                     4.7. Tumor Treating Field (TTF) Therapy
                         4.7.1. Tumor treating field (TTF) therapy market estimates and forecasts, 2018 to 2030 (USD Million)
                     4.8. Immunotherapy
                         4.8.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Glioblastoma Multiforme Treatment Market: Drug Class Estimates & Trend Analysis
                     5.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
                     5.2. Glioblastoma Multiforme Treatment Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
                     5.3. Temozolomide
                         5.3.1. Temozolomide market estimates and forecasts, 2018 to 2030 (USD Million)
                     5.4. Bevacizumab
                         5.4.1. Bevacizumab market estimates and forecasts, 2018 to 2030 (USD Million)
                     5.5. Lomustine
                         5.5.1. Lomustine market estimates and forecasts, 2018 to 2030 (USD Million)
                     5.6. Carmustine Wafers
                         5.6.1. Carmustine Wafers market estimates and forecasts, 2018 to 2030 (USD Million)
                     5.7. Others
                         5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Glioblastoma Multiforme Treatment Market: End Use Estimates & Trend Analysis
                     6.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
                     6.2. Glioblastoma Multiforme Treatment Market: End-use Movement & Market Share Analysis, 2022 & 2030
                     6.3. Hospitals
                         6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
                     6.4. Clinics
                         6.4.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
                     6.5. Ambulatory Surgical Centers
                         6.5.1. Ambulatory Surgical Centers market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Glioblastoma Multiforme Treatment Market: Regional Estimates & Trend Analysis
                     7.1. Regional Outlook
                     7.2. Glioblastoma Multiforme Treatment Market by Region: Key Takeaway
                     7.3. North America
                         7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.3.2. U.S.
                             7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.3.3. Canada
                             7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                     7.4. Europe
                         7.4.1. UK
                             7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.4.2. Germany
                             7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.4.3. France
                             7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.4.4. Italy
                             7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.4.5. Spain
                             7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.4.6. Sweden
                             7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.4.7. Norway
                             7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.4.8. Denmark
                             7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                     7.5. Asia Pacific
                         7.5.1. Japan
                             7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.5.2. China
                             7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.5.3. India
                             7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.5.4. Australia
                             7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.5.5. Thailand
                             7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.5.6. South Korea
                             7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                     7.6. Latin America
                         7.6.1. Brazil
                             7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.6.2. Mexico
                             7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.6.3. Argentina
                             7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                     7.7. MEA
                         7.7.1. Saudi Arabia
                             7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.7.2. South Africa
                             7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.7.3. UAE
                             7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
                         7.7.4. Kuwait
                             7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
                     8.1. Recent Developments & Impact Analysis, By Key Market Participants
                     8.2. Market Participant Categorization
                         8.2.1. Merck & Co., Inc.
                             8.2.1.1. Company overview
                             8.2.1.2. Financial performance
                             8.2.1.3. Product benchmarking
                             8.2.1.4. Strategic initiatives
                         8.2.2. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
                             8.2.2.1. Company overview
                             8.2.2.2. Financial performance
                             8.2.2.3. Product benchmarking
                             8.2.2.4. Strategic initiatives
                         8.2.3. Teva Pharmaceutical Industries Ltd.
                             8.2.3.1. Company overview
                             8.2.3.2. Financial performance
                             8.2.3.3. Product benchmarking
                             8.2.3.4. Strategic initiatives
                         8.2.4. Sun Pharmaceutical Industries Ltd.
                             8.2.4.1. Company overview
                             8.2.4.2. Financial performance
                             8.2.4.3. Product benchmarking
                             8.2.4.4. Strategic initiatives
                         8.2.5. Hoffmann-La Roche Ltd.
                             8.2.5.1. Company overview
                             8.2.5.2. Financial performance
                             8.2.5.3. Product benchmarking
                             8.2.5.4. Strategic initiatives
                         8.2.6. Pfizer, Inc.
                             8.2.6.1. Company overview
                             8.2.6.2. Financial performance
                             8.2.6.3. Product benchmarking
                             8.2.6.4. Strategic initiatives
                         8.2.7. Amgen, Inc.
                             8.2.7.1. Company overview
                             8.2.7.2. Financial performance
                             8.2.7.3. Product benchmarking
                             8.2.7.4. Strategic initiatives
                         8.2.8. Arbor Pharmaceuticals, LLC
                             8.2.8.1. Company overview
                             8.2.8.2. Financial performance
                             8.2.8.3. Product benchmarking
                             8.2.8.4. Strategic initiatives
                         8.2.9. Amneal Pharmaceuticals
                             8.2.9.1. Company overview
                             8.2.9.2. Financial performance
                             8.2.9.3. Product benchmarking
                             8.2.9.4. Strategic initiatives
                         8.2.10. Karyopharm Therapeutics, Inc.
                             8.2.10.1. Company overview
                             8.2.10.2. Financial performance
                             8.2.10.3. Product benchmarking
                             8.2.10.4. Strategic initiatives


List of Tables

Table 1 List of Abbreviations
Table 2 North America glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 3 North America glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 4 North America glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 5 North America glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 6 U.S. glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 7 U.S. glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 8 U.S. glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 9 Canada glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 10 Canada glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 11 Canada glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 12 Europe glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 13 Europe glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 14 Europe glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 15 Europe glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 16 Germany glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 17 Germany glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 18 Germany glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 19 UK glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 20 UK glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 21 UK glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 22 France glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 23 France glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 24 France glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 25 Italy glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 26 Italy glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 27 Italy glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 28 Spain glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 29 Spain glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 30 Spain glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 31 Sweden glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 32 Sweden glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 33 Sweden glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 34 Norway glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 35 Norway glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 36 Norway glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 37 Denmark glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 38 Denmark glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 39 Denmark glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 40 Asia Pacific glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 41 Asia Pacific glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 42 Asia Pacific glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 43 Asia Pacific glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 44 China glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 45 China glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 46 China glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 47 Japan glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 48 Japan glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 49 Japan glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 50 India glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 51 India glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 52 India glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 53 Thailand glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 54 Thailand glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 55 Thailand glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 56 South Korea glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 57 South Korea glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 58 South Korea glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 59 Australia glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 60 Australia glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 61 Australia glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 62 Latin America glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 63 Latin America glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 64 Latin America glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 65 Latin America glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 66 Brazil glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 67 Brazil glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 68 Brazil glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 69 Mexico glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 70 Mexico glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 71 Mexico glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 72 Argentina glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 73 Argentina glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 74 Argentina glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 75 Middle East and Africa glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 76 Middle East and Africa glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 77 Middle East and Africa glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 78 Middle East and Africa glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
Table 79 South Africa glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 80 South Africa glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 81 South Africa glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 85 UAE glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 86 UAE glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 87 UAE glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
Table 88 Kuwait glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
Table 89 Kuwait glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
Table 90 Kuwait glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Glioblastoma multiforme treatments: Market outlook
Fig. 9 Glioblastoma multiforme treatments: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Glioblastoma multiforme treatments market driver impact
Fig. 15 Glioblastoma multiforme treatments market restraint impact
Fig. 16 Glioblastoma multiforme treatments market strategic initiatives analysis
Fig. 17 Glioblastoma multiforme treatments market: Treatment movement analysis
Fig. 18 Glioblastoma multiforme treatments market: Treatment outlook and key takeaways
Fig. 19 Surgery market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Radiation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Targeted therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Tumor treating field (TTF) therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Immunotherapy therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Glioblastoma multiforme treatments market: Drug class movement analysis
Fig. 26 Glioblastoma multiforme treatments market: Drug class outlook and key takeaways
Fig. 27 Temozolomide market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Bevacizumab market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Lomustine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Carmustine wafers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Glioblastoma multiforme treatments market: End-use movement analysis
Fig. 33 Glioblastoma multiforme treatments market: End-use outlook and key takeaways
Fig. 34 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Ambulatory Surgical Centers market estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 37 Global glioblastoma multiforme treatments market: Regional movement analysis
Fig. 38 Global glioblastoma multiforme treatments market: Regional outlook and key takeaways
Fig. 39 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon